Oruka Therapeutics, Inc. — Director's Dealing 2012

Dec 20, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2012-12-18

Reporting Person: BRISTOW MICHAEL R (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-12-18	Common Stock	A	517116	$.4835	Acquired	834495	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-18	Common stock warrants (right to buy)	$.3897	A	387837	Acquired	2017-12-20	Common Stock (387837)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	280071	Direct

Footnotes

F1: The warrants are fully vested and exercisable upon issuance and have a contractual term of 5 years.